Kuiper, Josephina G. http://orcid.org/0000-0002-4487-3546
van Herk-Sukel, Myrthe P. P.
Castellsague, Jordi
Pottegård, Anton
Berglind, Ingegärd Anveden
Dedman, Daniel
Gutierrez, Lia
Calingaert, Brian
Hallas, Jesper
Sundström, Anders
Gallagher, Arlene M.
Kaye, James A.
Pardo, Carolina
Rothman, Kenneth J.
Perez-Gutthann, Susana
Funding for this research was provided by:
Astellas Netherlands
Article History
First Online: 7 May 2018
Disclosures
: Josephina G. Kuiper and Myrthe P.P. van Herk-Sukel are employees of the PHARMO Institute for Drug Outcomes Research. This independent research institute performs financially supported studies for government and related healthcare authorities and several pharmaceutical companies. Jordi Castellsague (retired), Lia Gutierrez, Brian Calingaert, Kenneth J. Rothman, James A. Kaye and Susana Perez-Gutthann are full-time employees of RTI Health Solutions, an independent nonprofit research organization that does work for government agencies and pharmaceutical companies. As employees of RTI Health Solutions, Susana Perez-Gutthann, Kenneth J. Rothman, and James A. Kaye, also participate in scientific advisory boards (for studies and medications) that are funded by pharmaceutical companies. Jesper Hallas and Anton Pottegård are employees of the Department of Public Health, University of Southern Denmark. They have participated in studies funded by pharmaceutical companies (Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Servier and Leo Pharma), all with funds paid to the institution where they were employed (no personal fees) and with no relation to the work reported in this paper. Daniel Dedman and Arlene Gallagher are employees of the Clinical Practice Research Datalink (CPRD), which provides contract research services for government and related healthcare authorities, and pharmaceutical companies. Ingegärd Anveden Berglind and Anders Sundström were both full-time employees of the Centre for Pharmacoepidemiology at the Karolinska Institutet during the conduct of the study. They have both taken part in studies undertaken at the Centre, financed by pharmaceutical companies, but have never received compensation personally from any company. Carolina Pardo is an employee of Astellas Pharma Europe.
: The study was funded by Astellas Pharma. In June 2016, LEO Pharma became the marketing authorization holder of Protopic® and provided partial funding. The contract grants the research team independent publication rights. The sponsor had no role in the data collection or analysis and was not involved in the interpretation of results; however, in line with the ENCePP Guide on Methodological Standards in Pharmacoepidemiology [CitationRef removed], the sponsor had the opportunity to view the results and interpretations included in the manuscript and provide comments before submission of the manuscript for publication.
: All authors had full access to all the data in the study and all take responsibility for the integrity of the data and the accuracy of the data analysis. The datasets generated during and/or analysed during the current study are not publicly available for privacy reasons.